Results 201 to 210 of about 35,993 (244)
Some of the next articles are maybe not open access.
2023
Abstract Adenosine diphosphate P2Y12 receptor antagonists inhibit platelet activation and subsequent aggregation. These agents may be used either alone or as part of dual antiplatelet therapy regimens with aspirin. P2Y12 inhibitors have proven useful in the treatment and prevention of several atherosclerotic cardiovascular conditions ...
Manan Pareek, Deepak L. Bhatt
openaire +1 more source
Abstract Adenosine diphosphate P2Y12 receptor antagonists inhibit platelet activation and subsequent aggregation. These agents may be used either alone or as part of dual antiplatelet therapy regimens with aspirin. P2Y12 inhibitors have proven useful in the treatment and prevention of several atherosclerotic cardiovascular conditions ...
Manan Pareek, Deepak L. Bhatt
openaire +1 more source
Current Opinion in Hematology, 2009
The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists.
openaire +2 more sources
The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists.
openaire +2 more sources
Role of P2Y12 Receptor in Thrombosis
2015P2Y12 receptor is a 342 amino acid Gi-coupled receptor predominantly expressed on platelets. P2Y12 receptor is physiologically activated by ADP and inhibits adenyl cyclase (AC) to decrease cyclic AMP (cAMP) level, resulting in platelet aggregation. It also activates PI3 kinase (PI3K) pathway leading to fibrinogen receptor activation, and may protect ...
Yaqi, Zhang, Si, Zhang, Zhongren, Ding
openaire +2 more sources
Characteristics of new P2Y12 inhibitors
Journal of Cardiovascular Medicine, 2013The options for antithrombotic therapy have recently been expanded, facilitating optimal tailored treatment. Dual antiplatelet therapy with aspirin and an approved adenosine diphosphate P2Y12 receptor antagonist is recommended for the management of patients with acute coronary syndromes (ACS).
openaire +2 more sources
State of the art of new P2Y12 antagonists
Internal and Emergency Medicine, 2010The interaction of ADP with its platelet receptor P2Y12 plays a crucial role in platelet activation and thrombogenesis. This article reviews the pharmacology and clinical trials of specific antagonists of P2Y12. Clopidogrel is a thienopyridine with proven antithrombotic efficacy, but it has some important drawbacks: (a) it is a pro-drug that needs to ...
M.N. Cattaneo, G. Podda
openaire +2 more sources
P2Y12 receptors: structure and function
Journal of Thrombosis and Haemostasis, 2015The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses. Defects of P2Y12R should be suspected when ADP, even at high concentrations (≥ 10 μm), is unable to induce full, irreversible ...
openaire +3 more sources
Responsiveness to P2Y12 receptor inhibitors
Current Opinion in Cardiology, 2011This review is aimed at describing the variability in response to P2Y12 inhibitor agents, and to focus on the main tests currently available to assess the responsiveness.There is high interindividual response variability to clopidogrel. Some patients do not respond to the drug; this condition can be due to patient-related factors (poor compliance ...
openaire +3 more sources
Switching P2Y12 Receptor Inhibiting Therapies
Interventional Cardiology Clinics, 2017Antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor is the cornerstone of treatment of patients with atherothrombotic disease manifestations. Switching between P2Y12 inhibitors occurs commonly in clinical practice for a variety of reasons, including safety, efficacy, adherence, and economic considerations.
Fabiana, Rollini +2 more
openaire +2 more sources
Effect of P2Y12 inhibitors on inflammation and immunity
Thrombosis and Haemostasis, 2015SummaryPlatelet P2Y12 inhibitors form a major part of the treatment strategy for patients with acute coronary syndromes (ACS) due to the importance of the platelet P2Y12 receptor in mediating the pathophysiology of arterial thrombosis. It has been increasingly recognised that platelets also have a critical role in inflammation and immune responses ...
Mark R, Thomas, Robert F, Storey
openaire +2 more sources
Thrombosis and Haemostasis, 2010
SummaryNovel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel. Cangrelor is an intravenously administered P2Y12 inhibitor that does not need metabolic conversion to an active metabolite for its antiplatelet action, and as a ...
Bouman, HJ +8 more
openaire +2 more sources
SummaryNovel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel. Cangrelor is an intravenously administered P2Y12 inhibitor that does not need metabolic conversion to an active metabolite for its antiplatelet action, and as a ...
Bouman, HJ +8 more
openaire +2 more sources